Skip to main content
SpringerLink
Log in

Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The clinical impact of monitoring serum p53 antibodies, carbohydrate antigen19-9, and carcinoembryonic antigen in patients with colorectal cancer has not been fully evaluated.

Methods

A total of 420 surgically treated stage II/III colorectal cancer patients were retrospectively analyzed. Among them, 101 patients developed disease recurrence. The prognostic impact of preoperative and recurrence levels of serum p53 antibodies, carbohydrate antigen19-9, and carcinoembryonic antigen status was evaluated.

Results

Although preoperative carcinoembryonic antigen- and carbohydrate antigen19-9-positive status was significantly associated with recurrence, preoperative serum p53 antibody levels were not. Among two marker combinations, carcinoembryonic antigen + serum p53 antibodies showed the highest positive rate at recurrence. Although carcinoembryonic antigen and carbohydrate antigen19-9 frequently converted from preoperative-negative status to positive status at recurrence, serum p53 antibodies converted to positive status in only one patient. Carcinoembryonic antigen- and carbohydrate antigen19-9-positive status were significant prognostic factors for overall survival after recurrence, but the presence of serum p53 antibodies at recurrence was not.

Conclusions

Postoperative serum p53 antibody status should only be followed in patients with preoperative-positive status. Carcinoembryonic antigen and carbohydrate antigen19-9 should be followed even in preoperative-negative patients. Unlike carcinoembryonic antigen- and carbohydrate antigen19-9-positive status, serum p53 antibody-positive status as recurrence was not a poor prognostic indicator.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Abbreviations

CEA:

Carcinoembryonic antigen

CA19-9:

Carbohydrate antigen 19-9

s-p53-Abs:

Serum p53 antibodies

References

  1. McKeown E, Nelson DW, Johnson EK et al (2014) Current approaches and challenges for monitoring treatment response in colon and rectal cancer. J Cancer 5:31–43

    Article  CAS  Google Scholar 

  2. Kahi CJ, Anderson JC, Rex DK (2013) Screening and surveillance for colorectal cancer: state of the art. Gastrointest Endosc 77:335–350

    Article  Google Scholar 

  3. Tokunaga R, Sakamoto Y, Nakagawa S et al (2017) The utility of tumor marker combination, including serum p53 antibody, in colorectal cancer treatment. Surg Today 47:636–642

    Article  CAS  Google Scholar 

  4. Kunizaki M, Sawai T, Takeshita H et al (2016) Clinical value of serum p53 antibody in the diagnosis and prognosis of colorectal cancer. Anticancer Res 36:4171–4175

    PubMed  CAS  Google Scholar 

  5. Ochiai H, Ohishi T, Osumi K et al (2012) Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. Surg Today 42:164–168

    Article  CAS  Google Scholar 

  6. Yamaguchi T, Takii Y, Maruyama S (2013) Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients. Surg Today 44:1529–1535

    Article  CAS  Google Scholar 

  7. Suzuki T, Funahashi K, Ushigome M et al (2017) Diagnostic and prognostic impact of serum p53 anti body titration in colorectal cancer. Toho J Med 11:107–115

    Google Scholar 

  8. Suzuki T, Shimada H, Ushigome M et al (2016) Three-years monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer. Clin J Gastroenterol 9(55–58):16

    Google Scholar 

  9. Shibutani M, Maeda K, Nagahara H et al (2014) Hirakawa K Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer. Anticancer Res 34:3753–3758

    PubMed  Google Scholar 

  10. Kawahara H, Watanabe K, Enomoto H et al (2013) Normalization of serum p53 antibody levels in patients after curative resection for colorectal cancer. Anticancer Res 33:2221–2225

    PubMed  CAS  Google Scholar 

  11. Sobin LH, Gospodarowicz MK, Wittekind C (2010) TNM classification of malignant tumors, 7th edn. Wiley-Blackwell, Hoboken

    Google Scholar 

  12. Suzuki T, Yajima S, Ishioka N et al (2018) Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma. Esophagus 15:294–300

    Article  Google Scholar 

  13. Shimada H, Ochiai T, Nomura F (2003) Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multi-institutional analysis by the Japan p53 Antibody Research Group. Cancer 97:682–689

    Article  Google Scholar 

  14. Ito M, Oshima Y, Yajima S et al (2019) Diagnostic impact of high serum midkine level in patients with gastric cancer. Ann Gastroenterol Surg. 3(2):195–201

    Article  Google Scholar 

  15. Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl 48:452–458

    Article  CAS  Google Scholar 

  16. Shimada H, Shiratori T, Takeda A et al (2009) Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg. 33:272–277

    Article  Google Scholar 

  17. Tang R, Yeh CY, Wang JY et al (2009) Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection. Ann Surg Oncol 16:2516–2523

    Article  Google Scholar 

  18. Ushigome M, Nabeya Y, Soda H et al (2018) Multi-panel assay of serum autoantibodies in colorectal cancer. Int J Clin Oncol 23:917–923

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was partially supported by JSPS KAKENHI (grant number 26462029). The authors would like to thank MARUZEN-YUSHODO Co., Ltd. (https://kw.maruzen.co.jp/kousei-honyaku/) for the English language editing.

Author information

Authors and Affiliations

  1. Department of Surgery, School of Medicine, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 142-8541, Japan

    Mitsunori Ushigome, Hideaki Shimada, Yasuyuki Miura, Kimihiko Yoshida, Tomonori Kaneko, Takamaru Koda, Yasuo Nagashima, Takayuki Suzuki, Satoru Kagami & Kimihiko Funahashi

  2. Department of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 142-8541, Japan

    Hideaki Shimada

Authors
  1. Mitsunori Ushigome
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideaki Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuyuki Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kimihiko Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomonori Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takamaru Koda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasuo Nagashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takayuki Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Satoru Kagami
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kimihiko Funahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideaki Shimada.

Ethics declarations

Conflict of interest

The authors have no conflict of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ushigome, M., Shimada, H., Miura, Y. et al. Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA. Int J Clin Oncol 25, 622–632 (2020). https://doi.org/10.1007/s10147-019-01597-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-019-01597-6

Keywords

Search

Navigation